Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $27.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target dropped by equities researchers at HC Wainwright from $28.00 to $27.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 111.60% from the company’s current price.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. decreased their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. JMP Securities dropped their target price on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday. Finally, StockNews.com downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $12.76 on Tuesday. The firm has a market cap of $269.95 million, a PE ratio of -2.04 and a beta of 0.54. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $28.25. The firm has a 50 day simple moving average of $14.88 and a 200 day simple moving average of $12.08.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -4.9 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its stake in Enanta Pharmaceuticals by 417.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,281 shares in the last quarter. Clearstead Advisors LLC bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $57,000. Quantbot Technologies LP increased its holdings in Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,900 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new position in Enanta Pharmaceuticals in the third quarter worth approximately $113,000. Finally, Laurion Capital Management LP bought a new position in Enanta Pharmaceuticals during the third quarter valued at approximately $126,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.